Madeleine Williams
Stock Analyst at Canaccord Genuity
(0.20)
# 4,713
Out of 5,125 analysts
99
Total ratings
29.4%
Success rate
-12.8%
Average return
Main Sectors:
Stocks Rated by Madeleine Williams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: CGS Cogstate Limited | Reiterated: Buy | $4.15 | $3.64 | +14.01% | 7 | Oct 30, 2026 | |
| ASX: MSB Mesoblast Limited | Reiterated: Buy | $3.56 → $3.52 | $2.03 | +73.40% | 8 | Oct 29, 2026 | |
| ASX: BOT Botanix Pharmaceuticals Limited | Downgraded: Hold | $0.14 → $0.01 | $0.01 | +11.11% | 7 | Oct 27, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Reiterated: Buy | $2.84 → $3.20 | $1.91 | +67.98% | 4 | Oct 23, 2026 | |
| ASX: CU6 Clarity Pharmaceuticals Ltd | Reiterated: Buy | $8.41 → $8.38 | $1.66 | +404.82% | 13 | Sep 16, 2026 | |
| ASX: NEU Neuren Pharmaceuticals Limited | Reiterated: Buy | $24.76 | $23.96 | +3.34% | 8 | Aug 29, 2026 | |
| ASX: CUV Clinuvel Pharmaceuticals Limited | Downgraded: Hold | $27.90 → $9.52 | $7.55 | +26.09% | 3 | Aug 27, 2026 | |
| ASX: MYX Mayne Pharma Group Limited | Reiterated: Buy | $3.83 → $3.75 | $3.36 | +11.61% | 5 | Aug 27, 2026 | |
| ASX: EBR EBR Systems, Inc. | Reiterated: Buy | $2.27 → $1.91 | $0.17 | +1,023.53% | 12 | Aug 21, 2026 | |
| ASX: ATH Alterity Therapeutics Limited | Reiterated: Buy | $0.95 | $0.28 | +245.45% | 5 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.27 → $0.32 | $0.26 | +25.49% | 3 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $0.15 | $0.01 | +971.43% | 9 | Jul 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.28 | $1.27 | +79.53% | 7 | Jul 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180.82 → $168.62 | $207.31 | -18.66% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1.27 → $0.40 | $0.03 | +1,500.00% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27.33 → $27.41 | $14.02 | n/a | 2 | Oct 15, 2025 |
Cogstate Limited
Oct 30, 2026
Reiterated: Buy
Price Target: $4.15
Current: $3.64
Upside: +14.01%
Mesoblast Limited
Oct 29, 2026
Reiterated: Buy
Price Target: $3.56 → $3.52
Current: $2.03
Upside: +73.40%
Botanix Pharmaceuticals Limited
Oct 27, 2026
Downgraded: Hold
Price Target: $0.14 → $0.01
Current: $0.01
Upside: +11.11%
PYC Therapeutics Limited
Oct 23, 2026
Reiterated: Buy
Price Target: $2.84 → $3.20
Current: $1.91
Upside: +67.98%
Clarity Pharmaceuticals Ltd
Sep 16, 2026
Reiterated: Buy
Price Target: $8.41 → $8.38
Current: $1.66
Upside: +404.82%
Neuren Pharmaceuticals Limited
Aug 29, 2026
Reiterated: Buy
Price Target: $24.76
Current: $23.96
Upside: +3.34%
Clinuvel Pharmaceuticals Limited
Aug 27, 2026
Downgraded: Hold
Price Target: $27.90 → $9.52
Current: $7.55
Upside: +26.09%
Mayne Pharma Group Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $3.83 → $3.75
Current: $3.36
Upside: +11.61%
EBR Systems, Inc.
Aug 21, 2026
Reiterated: Buy
Price Target: $2.27 → $1.91
Current: $0.17
Upside: +1,023.53%
Alterity Therapeutics Limited
Aug 13, 2026
Reiterated: Buy
Price Target: $0.95
Current: $0.28
Upside: +245.45%
Jul 30, 2026
Reiterated: Hold
Price Target: $0.27 → $0.32
Current: $0.26
Upside: +25.49%
Jul 8, 2026
Reiterated: Buy
Price Target: $0.15
Current: $0.01
Upside: +971.43%
Jul 4, 2026
Reiterated: Buy
Price Target: $2.28
Current: $1.27
Upside: +79.53%
May 12, 2026
Reiterated: Buy
Price Target: $180.82 → $168.62
Current: $207.31
Upside: -18.66%
Mar 13, 2026
Reiterated: Buy
Price Target: $1.27 → $0.40
Current: $0.03
Upside: +1,500.00%
Oct 15, 2025
Reiterated: Buy
Price Target: $27.33 → $27.41
Current: $14.02
Upside: n/a